PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2014.
“2014 was a significant year for Anacor. Our first drug, KERYDIN®, was approved by the FDA for the topical treatment of onychomycosis of the toenails. KERYDIN is the first oxaborole antifungal product approved for use in the United States. We also entered into an exclusive U.S. agreement with Sandoz Inc. to commercialize KERYDIN, which was launched in September through its branded dermatology division, PharmaDerm,” said Paul L. Berns, Chairman and Chief Executive Officer of Anacor.
Help employers find you! Check out all the jobs and post your resume.
“2014 was a significant year for Anacor. Our first drug, KERYDIN®, was approved by the FDA for the topical treatment of onychomycosis of the toenails. KERYDIN is the first oxaborole antifungal product approved for use in the United States. We also entered into an exclusive U.S. agreement with Sandoz Inc. to commercialize KERYDIN, which was launched in September through its branded dermatology division, PharmaDerm,” said Paul L. Berns, Chairman and Chief Executive Officer of Anacor.
Help employers find you! Check out all the jobs and post your resume.
